TheStreet.com TV Recap: Countering Nastech Naysayers

Cramer sees the pharma stock as a speculative play with potentially huge upside.
Author:
Publish date:

Although

Nastech

(NSTK)

is not the most well-liked stock, Jim Cramer believes it is a speculative play that could go up big, he said on TheStreet.com Wall St. Confidential

Web video Tuesday.

Sure, an obesity-treament deal with

Merck

(MRK) - Get Report

was derailed, a deal with

Novo Nordisk

(NVO) - Get Report

hasn't been announced yet, and its big deal with

Procter & Gamble

(PG) - Get Report

on a nasal spray didn't produce anything. And sure, Nastech has only $60 million left in the bank, Cramer said.

But Cramer expects every one of Nastech's deals should have news between now and Christmas. And given that this company has disappointed time and again, "if any one of them comes through, I think you have a home run," he said.

Nastech is not only doing fabulous work in bone growth, it has insulin, obesity, RNA interference and autism plays, Cramer said.

What's more is the pharmaceutical has got all the best doctors in each one of its plays, patents, and great partners in Merck, Procter & Gamble and Novo Nordisk, Cramer said.

"I have faith in it even though no one else does because if you look at the doctors who work there, if you look at the people who've gone there, and you look at their reputations, there's clearly something going on that's positive," Cramer said.

Further, he believes Nastech's tie-in with Procter & Gamble on bone growth could be "gigantic." There are some milestones people should look out for here, Cramer said, and one is a $5 million payment from P&G. "If we get that within the next few weeks, I think it would be very big," he said.

Nastech could also sell off its RNAi play, Cramer said. "I can't tell you how hot RNAi has been because everybody thinks it's a new genetic weapon against illness," he said. "They would use theirs for the bird flu.

"This is a company where there are a lot of ways to win," Cramer continued. "I would not be using this company as my speculative play if it had been doing well. It's the disappointment factor and the write-off of NSTK that makes it so exciting for me."

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click

here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click

here to order his book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.